A cost-effectiveness analysis of erthropoietin in ICU patients
Анализ экономической эффективности применения эритропоэтина у пациентов отделений интенсивной терапии
2004-01-01
SCID: 54.1/c77f668r
Discuss with AI
ICU patientsPRBC transfusion requirementcost-effectiveness analysispacked red blood cell transfusionrecombinant human erythropoietin
Figures from the paper
Abstract (AI)
Recombinant human erythropoietin (rhEPO) has been shown to decrease the packed red blood cell (PRBC) transfusion requirement by about 20% among ICU patients admitted for longer than 48 hours. Despite this, its use has not been widely instituted, in part due to its cost.
Key Findings
1
Despite reducing transfusion needs, rhEPO has not been widely adopted partly because of its cost.
2
Recombinant human erythropoietin reduces packed red blood cell transfusion requirements by approximately 20% in ICU patients hospitalized longer than 48 hours.
3
The study evaluates the cost-effectiveness of erythropoietin use in critically ill ICU patients.
Research Object
recombinant human erythropoietin (rhEPO) use in ICU patients admitted for longer than 48 hours
Research Subject
cost-effectiveness in reducing packed red blood cell (PRBC) transfusion requirements
Publication Details
Publication Date
2004-01-01
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest